Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avita HP is a topical triple-combination pharmaceutical cream primarily indicated for the short-term treatment of moderate-to-severe melasma of the face. It contains three active ingredients that work synergistically to address hyperpigmentation: hydroquinone, tretinoin, and mometasone furoate. Hydroquinone acts as a depigmenting agent by inhibiting the enzyme tyrosinase, which is essential for melanin synthesis. Tretinoin, a retinoid, promotes epidermal cell turnover and the shedding of pigmented keratinocytes, while also enhancing the penetration of hydroquinone into the skin. Mometasone furoate is a medium-potency corticosteroid that provides anti-inflammatory and antipruritic effects, helping to mitigate the skin irritation and erythema frequently caused by the other two components. This combination is designed to provide superior efficacy in skin lightening compared to the individual components while managing local tolerability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Avita HP.